Rochester, NY – March 10, 2026 – The Huntington Study Group (HSG), in collaboration with Vanderbilt University Medical Center (VUMC),
Huntington Study Group Announces Executive Director of Clinical Operations Rochester, NY — March 31, 2025 — The Huntington Study Group®
Huntington Study Group and HD Genetics Collaborate to Better Serve HD Gene Positive Patients Rochester, NY – September 5, 2024
Huntington Study Group Announces New CEO Rochester, NY – August 20, 2024 – The Huntington Study Group® and HSG Clinical Research, Inc.
Huntington Study Group Announces Launch of LEAD-HD Observational Study Rochester, NY – July, 15, 2024 – The Huntington Study Group® and HSG
Huntington Study Group Launches Project AWARE 2.0 Observational Study Rochester, NY – April 10, 2024 – The Huntington Study Group®
Rochester, NY — January 22, 2024 — The Huntington Study Group® (HSG), together with its wholly owned subsidiary, HSG Clinical Research, Inc.,
Rochester, NY — December 13, 2023 — The Huntington Study Group together with its wholly-owned clinical research organization, HSG Clinical Research, Inc.
Rochester, NY — November 20, 2023 — The Huntington Study Group® (HSG®), a world leader in conducting clinical trials and providing educational
Rochester, NY, October 11, 2023 – The Huntington Study Group® (HSG) together with its wholly owned subsidiary, HSG Clinical Research,
Rochester, New York, August 18, 2023 – The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc.,
The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in conducting
Rochester and New York City, New York, July 25, 2023 — HSG Clinical Research, Inc. — the Huntington Study Group’s clinical
Rochester, NY – June 1, 2023 – The Huntington Study Group (HSG), with a mission of accelerating treatments that make a difference for
Neurocrine Biosciences, Inc. today announced that the complete study results from its Phase 3 KINECT™-HD study investigating valbenazine for the
Rochester, NY – May 16, 2023 – The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc., announces
Rochester, NY, March 30, 2023 — The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc.,
Rochester, NY — March 21, 2023 — The Huntington Study Group (HSG), a world leader in conducting clinical trials and providing
Rochester, NY — January 10, 2023 — The Huntington Study Group (HSG), a world leader in clinical research for Huntington’s Disease (HD) for
Rochester, NY – December 5, 2022 – The Huntington Study Group (HSG), a world leader in conducting clinical trials for
Rochester, NY – November 29, 2022 – The Huntington Study Group (HSG), a world leader in conducting clinical trials for
Rochester, NY — October 25, 2022 — The Huntington Study Group (HSG), a world leader in clinical research for Huntington’s Disease (HD) for
Rochester, N.Y. — October 18, 2022 — The Huntington Study Group (HSG), a world leader in clinical research for Huntington’s Disease (HD) for
Rochester, N.Y. — October 12, 2022 — The Huntington Study Group (HSG), a world leader in conducting clinical trials for Huntington’s Disease
July 2022 The Unified Huntington’s Disease Rating Scale (UHDRS®) was established to routinely assess motor, cognitive, behavioral and function in
July 2022 HSG Clinical Research, Inc. (HSGCR) was established as a wholly owned for-profit subsidiary of the Huntington Study Group,
July 2022 Dear HSG Investigator and Coordinator Members, Thank you for participating in the election of the Co-Chairs of the
July 2022 On May 12, 2022, Sandra Kostyk (Ohio State) and Sam Frank (Beth Israel Deaconess Medical Center) were elected
—– July 2022 KINECT-HD2 is being conducted by Neurocrine Biosciences, Inc. (“Sponsor”) in partnership with the Huntington Study Group (HSG).
July 2022 Start Booking Your Travel Now – HSG 2022 ANNUAL MEETING Returns to In-Person! Special Sessions –by invitation only(Wednesday
July 2022 The HSG is excited to share that the pilot study, Making HD Voices Heard, on the new online
SAN DIEGO, Dec. 7, 2021 – Neurocrine Biosciences (Nasdaq: NBIX) today announced positive top-line data from its Phase 3 KINECT-HD
Rochester, N.Y. — September 17, 2020 —The Huntington Study Group (“HSG”), a world leader in clinical research for Huntington’s Disease
The Huntington Study Group (HSG), a world leader in spearheading research and conducting clinical trials in Huntington disease (HD), has
The Huntington Study Group announced that it is taking the early and proactive step of moving this year’s annual meeting,
For Immediate Release: February 27, 2020 The Huntington Study Group (HSG), a world leader in spearheading research and conducting clinical
For Immediate Release: November 14, 2019 The Huntington Study Group (HSG), a world leader in spearheading research and conducting clinical
For Immediate Release: April 12, 2019 The Huntington Study Group (HSG) was recently featured on morning programming at two local
For Immediate Release: March 25, 2019 The Huntington Study Group (HSG), a world leader in spearheading research and conducting clinical
Rochester, NY – March 11, 2019 Today the Huntington Study Group (HSG) announced the restructuring of its Education Committee into
Beginning February 1, 2019, the Huntington Study Group (HSG) will offer the latest update to its popular online learning program,
The Huntington Study Group announces Sacramento, California as the location for this year’s annual meeting: HSG 2019. Dr. Vicki Wheelock
The Huntington Study Group (HSG) is pleased to announce the that Dr. Nicolò Zarotti has been named recipient of the
The Huntington Study Group (HSG) is pleased to announce that Andrew Feigin, MD, and Elise Kayson, MS, ANP, have been
JAMA Neurology paper published today from ARC-HD Trial People with Huntington disease-associated chorea can safely convert overnight from tetrabenazine to
The U.S. Food and Drug Administration (FDA) today approved SD-809 (deutetrabenazine), the second drug approved for use in the United
Help4HD gave the Huntington Study Group the opportunity on its radio show to update the community on our many current
The Huntington Study Group held its 23rd Annual Meeting and 10th Annual Clinical Research Symposium November 2-5, in Nashville, TN.
Vaccinex, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VX15 as
JAMA publishes First-HD study People with Huntington disease experienced improvements in chorea while taking deutetrabenazine (SD-809) compared to placebo, according
Teva Pharmaceuticals Industries announced yesterday that the U.S. Food and Drug Administration (FDA) has asked for more data on SD-809
Vaccinex Inc. completed enrollment of cohort A in its SIGNAL Clinical Trial, a randomized Phase 2 study to assess the
Participating in Huntington’s disease research is important to Katie Moser. Katie, 34, is gene positive and showing no symptoms of
PRIDE-HD Study Enrolling Patients Globally to Further Evaluate Pridopidine for the Symptomatic Treatment of Huntington’s Disease – Study initiation represents
Teva and Active Biotech Announce Expansion of Laquinimod Clinical Development Program with New Trial in Primary Progressive Multiple Sclerosis and
Auspex Announces Positive Topline Results From Registration Trial of SD-809 for Chorea Associated With Huntington’s Disease Pivotal Phase 3 Trial
Announcement of CREST-E Early Study Closure October 2014 The National Center for Complementary and Alternative Medicine (NCCAM), part of the
Announcement of 2CARE Early Study Closure August 2014 The National Institute of Neurological Disorders and Stroke (NINDS) stopped its study
2CARE (Coenzyme Q10 in Huntington’s Disease) Study Update September, 2012 Enrollment for the 2CARE study was closed on 25 July
FOR IMMEDIATE RELEASE Huntington Study Group to Conduct Therapeutic Research Study in Pre-manifest Huntington’s Disease May 14, 2009 – Physicians at
FOR IMMEDIATE RELEASE HSG Begins Phase IIb Study in Huntington Disease (HD) December 2, 2008 – The Huntington Study Group
